SAN DIEGO--(BUSINESS WIRE)--Sequenom, Inc. (NASDAQ:SQNM), a leading provider of fine mapping genotyping, methylation and gene expression analysis solutions, today announced the commercial launch of its Assays-By-SequenomTM service. This service provides customers with the flexibility to choose any SNP of interest combined with the convenience and reliability of off-the-shelf pre-validated assay reagents. The new offering includes assay design for customer specified SNPs along with delivery of ready-to-use functionally validated assays for use with the MassARRAY® platform.
